AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02367170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Volitional Measurement of Maximal Inspiratory Pressure (MIP)
Description: MIP is tested on all subjects on day 1, every 7 days after and on the last day of participation. To measure MIP, a subject will be suctioned, disconnected from the ventilator, and instructed to take a few spontaneous breaths. A 1-way exhalation valve connected to a NICO respiratory monitor will be placed on the ET/tracheotomy tube. The subject will be instructed to inhale and exhale as forcefully as possible for 20 seconds, followed by at least 2 minutes of rest on full mechanical ventilation support. MIP trials will be repeated 3 times, and the greatest negative pressure recorded with a NICO respiratory monitor connected to a laptop computer, which will digitize airway pressure, flow and volume signals at 100Hz. This allows for analysis of the individual pressure waves, facilitating pre-post comparisons of MIP at specific time points during inspiration.
Study NCT02367170 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Volitional Measurement of Maximal Inspiratory Pressure (MIP)
Description: MIP is tested on all subjects on day 1, every 7 days after and on the last day of participation. To measure MIP, a subject will be suctioned, disconnected from the ventilator, and instructed to take a few spontaneous breaths. A 1-way exhalation valve connected to a NICO respiratory monitor will be placed on the ET/tracheotomy tube. The subject will be instructed to inhale and exhale as forcefully as possible for 20 seconds, followed by at least 2 minutes of rest on full mechanical ventilation support. MIP trials will be repeated 3 times, and the greatest negative pressure recorded with a NICO respiratory monitor connected to a laptop computer, which will digitize airway pressure, flow and volume signals at 100Hz. This allows for analysis of the individual pressure waves, facilitating pre-post comparisons of MIP at specific time points during inspiration.
Study NCT02367170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Strength Training (IMST)
Description: Occurs 5 days/wk using threshold IMST device-Respironics model 735. Prior to training, cuff pressure is assessed, FiO2 increased for 2 min. to keep O2 sats ≥92%. The ventilator circuit is disconnected, IMST device is attached to endotracheal or tracheotomy tube and subject is instructed to exhale then forcefully inhale for 10 breaths. The initial setting of device is set to -5cmH2O, subject must generate a negative inspiratory pressure more negative than -5cmH2O to open spring-loaded valve and receive inspiratory airflow. Pressure setting is made more negative/difficult to open by 2-5cm every few breaths until a setting is found where the patient has difficulty fully opening valve, resulting in valve flutter noise. Training pressure is then made more positive /easier by 2-4cm of H2O, so subject can fully open valve, and 4 sets of 6-10 breaths are completed. Training pressures advanced as rapidly as possible, provided the patient is able to open the valve withoutvalve flutternoise.
Study NCT02367170 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM Inspiratory Muscle Strength Training (IMST)
Description: Training will also be conducted 5 days/wk with an identical IMST device that has been modified by removing the valve leaflet, which essentially removes all inspiratory loading by the device. The modified SHAM IMST device makes a whistling sound during inspiration, which enhances the sham effect. For SHAM treatment, supplemental oxygen FiO2 will be increased for two minute prior to each bout. The ventilator will be disconnected and a SHAM device will be attached to the endotracheal or tracheostomy tube. The subject will be instructed to take 6-10 breaths with a normal tidal volume through the SHAM device and will be reconnected to the ventilator for a 2-minute rest period. The process will be repeated 3 more times for a total of 4 sets of 6-10 breaths.
Study NCT02675374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexchlorpheniramine (Polaramine®) injection
Description: 5 minutes before CPB, patients will receive 10 mg (2 ml) of Polaramine®
Study NCT02675374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: 5 minutes before CPB, patients will receive 2 ml of normal saline
Study NCT04701424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CamAPS HX Closed-loop
Description: The CamAPS HX closed-loop system comprises:~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea) Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA) An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump Glooko/Diasend cloud upload system to monitor CGM/insulin data.
Study NCT04701424 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multiple Daily Insulin Injections (Control)
Description: Multiple Daily Insulin Injections with masked Dexcom G6 CGM sensor (Dexcom, Northridge, CA, USA)
Study NCT04067193 — intervention group
Intervention type: OTHER
Intervention: usability survey
Description: usability survey composed of subpart: System Usability Scale, questions about ergonomic, questions about design, question about global satisfaction.
Study NCT00294892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbamazepine and nevirapine
Description: Carbamazepine 400mg and Nevirapine 200mg are taken just before delivery during labor.
Study NCT00294892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nevirapine
Description: Nevirapine 200mg is taken prior to delivery during labor.
Study NCT03003364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XCEL-UMC-BETA
Description: Intrathecal allogeneic cell therapy in a blinded syringe
Study NCT00323622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfadoxine-pyrimethamine
Description: 1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
Study NCT01333579 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation, frequency of 1Hz, once a day for ten days.
Study NCT04824976 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberry
Description: freeze-dried Northern highbush blueberry powder twice daily 15g = 60kcal
Study NCT04824976 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched powder maltodextrin twice daily = 60kcal
Study NCT04529915 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Exosome sampling
Description: * Centrifugation of blood plasma~* Size exclusion chromatography~* ELISA assay, Western blotting~* Deep-learning analysis
Study NCT03929510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-PF-06651600
Description: Oral solution of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi radioactivity
Study NCT03929510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-PF-06651600 IV
Description: IV solution 60 micrograms of 14C labeled PF-06651600 containing approximately 300 nCi radioactivity
Study NCT03929510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: Oral solution 200mg
Study NCT03445520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Coaching Group
Description: Parents in this group receive six, 1 hour, coaching sessions with a research staff coach, to discuss key information about transitions (knowing parent's rights about special education services, communicating effectively with school staff, knowing the roles of the school team members, how to develop and share your Snapshot, and what to do with your child over the summer to help with the transition). The coach will encourage the parent to identify a school staff member to help with preparing for the transition. If the post transition school team is not able to participate in a pre-transition meeting, then the coach will encourage the parent to share the Student Snapshot with the post-transition teacher(s) and school team when the new school year begins in the Fall.
Study NCT04087174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Patients will receive multiple oral dose of capivasertib.
Study NCT04087174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Patients will receive 160 mg oral dose of enzalutamide.
Study NCT04087174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Patients will receive 1000 mg oral dose of abiraterone.
Study NCT00747461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CryoSpray Ablation
Description: Cryospray Ablation up to 4 -5 second cycles for up to 4 treatments in the first 30 days
Study NCT00839852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine was supplied in capsules.
Study NCT02838446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Description: Graded Motor Imagery has three stages:~Lateralisation (2 or 3 weeks) Motor Imagery (2 or 3 weeks) Mirror Therapy (2 or 3 weeks)
Study NCT02838446 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Therapy
Description: Graded Motor Imagery has three stages:~Lateralisation (2 or 3 weeks) Motor Imagery (2 or 3 weeks) Mirror Therapy (2 or 3 weeks)
Study NCT03134833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Messaging & Monitoring
Description: Youth will receive messages 1-5 messages per day for 24 months. Message banks of about 750 text messages (70-120/domain) will focus on the HIV Prevention Continuum, with messages dedicated to healthcare, wellness, sexual health, drug use and medication reminders (e.g., for PrEP) for MSM and non-MSM. Youth will be able to choose the time that they receive daily texts. Text timing and the frequency of texts (e.g., if the youth comes out) will be updated at 4-month intervals.~Youth will complete weekly monitoring surveys by text message. The survey will cover seven domains related to the HIV Prevention Continuum. In case of non-response, reminder messages will be sent to the youth. After three days of non-response, a follow-telephone call will occur.
Study NCT03134833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support
Description: Youth will be enrolled in online, private discussion groups.~Peer Support will be offered by fellow participants and/or Youth Advisory Board members that have been trained in basic information on HIV, STI, drug use, mental health, homelessness, and stigma; using social media to create wall posts and use chat functions; and, how to initiate conversations on sensitive topics. By posting and responding to messages, Peer Supporters will encourage and broadly guide conversation related to the HIV Prevention Continuum, and other relevant topics.~Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content.
Study NCT03134833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Youth will have access to a dedicated Coach to assist with crisis support and problem-solving, linkage to HIV and related services (e.g., for substance use, mental health), and care coordination. Coaches will be accessible electronically (using social media, e-mail, text messaging) and by phone. In cases where virtual support has failed, Coaches will be available in-person (e.g., to accompany a participant to a doctor's appointment). We anticipate that Coaches will provide each youth with 10 hours of support, on average, per year.
Study NCT01222624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PankoMab-GEX™
Study NCT03561116 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: XAN
Description: Daily intake of a sachet containing 12 mg of XAN
Study NCT02243592 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Undergo sequencing and SNP analysis
Study NCT03561116 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily intake of a sachet containing excipient
Study NCT02002273 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Switching level of suction
Study NCT02725931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) plus PA-focused intervention
Description: Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychosocial support and education sessions (once a week). Patients will also have their PA levels monitored on weeks (W) 1, 7 and 12 and receive feedback in the following weeks.
Study NCT00216710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Visiting
Study NCT03860597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.
Study NCT03860597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.
Study NCT04324931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomechanical corrections
Description: Biomechanical corrections is to be done to correct the varus deformity of knee joint and for pain management.
Study NCT04324931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: Conventional therapy includes Hydrocollatoral pack for 20 minutes, Interferential therapy for 15 minutes beat frequency 100 Hz, Sweep frequency 150 Hz and exercise program of 3 sessions for 20 minutes on alternative days for 3 weeks for management of knee osteoarthritis.
Study NCT01743417 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerised cognitive rehabilitation training
Description: 24 sessions of computerised bran training will be provided for 8 weeks (+/-2) with about 3 sessions per week to the intervention arm and active control arms. The program will be programmed to increases in difficulty for the intervention arm. In the active control arms, the difficulty level will not change.
Study NCT01743417 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerised cognitive rehabilitation training
Description: 24 sessions of computerised bran training will be provided for 8 weeks (+/-2) with about 3 sessions per week to the intervention arm and active control arms. The program will be programmed to increases in difficulty for the intervention arm. In the active control arms, the difficulty level will not change.
Study NCT04043728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol adapted for smoking cessation
Description: Treatment components are cognitive-behavioral strategies adapted from the Unified Protocol (UP) for the Transdiagnostic Treatment of Emotional Disorders. Behavioral counseling strategies for smoking cessation, drawn from current US Public Health Service guidelines, are incorporated in each treatment module. All participants will be provided with the American Lung Association Freedom from Smoking guide to aid in their quit attempt.
Study NCT03003364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XCEL-UMC-BETA
Description: Intrathecal allogeneic cell therapy in a blinded syringe
Study NCT03003364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in a blinded syringe
Study NCT03003364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo in a blinded syringe
Study NCT00377572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
Study NCT00377572 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: omalizumab placebo
Description: Subcutaneous injections of placebo will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
Study NCT04006938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Bout ('S')
Description: Each subject will perform a single bout of 30-minutes of moderate-intensity cycling before breakfast
Study NCT04006938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Bout ('M')
Description: Each subject will perform three (3) 10-minute bouts of moderate intensity cycling before breakfast, lunch and dinner
Study NCT02367170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diaphragm thickness measurement
Description: Ultrasound will be used to obtain measurements of the thickness of the right hemidiaphragm. Ultrasonography of the diaphragm will be performed upon enrollment, every 2-4 days during hospitalization and as long as the patient is hospitalized or up to 28 days of participation.
Study NCT02367170 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Diaphragm thickness measurement
Description: Ultrasound will be used to obtain measurements of the thickness of the right hemidiaphragm. Ultrasonography of the diaphragm will be performed upon enrollment, every 2-4 days during hospitalization and as long as the patient is hospitalized or up to 28 days of participation.
Study NCT02367170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and Urine samples
Description: Peripheral blood and urine samples will be collected once upon study entry day (+/- 2 days), once every 2-4 days and once on final day of study participation (+/- 2days).
Study NCT00323622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amodiaquine
Description: 1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
Study NCT00323622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amodiaquine
Description: 1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
Study NCT02367170 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Blood and Urine samples
Description: Peripheral blood and urine samples will be collected once upon study entry day (+/- 2 days), once every 2-4 days and once on final day of study participation (+/- 2days).
Study NCT03032185 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Elevtrical Nerve Stimulation
Study NCT03032185 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Elevtrical Nerve Stimulation
Study NCT00851734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voclosporin ophthalmic solution
Description: 0.02%, 0.2% t.i.d. or b.i.d.
Study NCT00851734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: voclosporin ophthalmic solution
Description: 0.02%, 0.2% t.i.d. or b.i.d.
Study NCT01737008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacomitinib
Description: Tablets are administered orally or through a G-Tube, and can be taken with or without food.
Study NCT01737008 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Intensity modulated radiation therapy (IMRT) delivered using 4 or 6 MV photons. Patients will receive either the standard dose fractionation radiotherapy or accelerated fractionation radiotherapy.
Study NCT01737008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: If selected for this arm, cisplatin will be administered intravenously every three weeks after receiving premedications.
Study NCT06222619 — intervention group
Intervention type: PROCEDURE
Intervention: Potal vein embilization
Description: Portal vein of involved bile duct is embolized to increase the volume of remnant liver.
Study NCT01683695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 557
Description: AMG 557 will be administered as subcutaneous injections in the anterior abdomen of the subjects.
Study NCT01683695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo will be administered as subcutaneous injections in the anterior abdomen of the subjects.
Study NCT02734004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib
Study NCT02734004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736
Study NCT00403052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1018 ISS immunostimulatory oligonucleotide
Description: 6 weekly subcutaneous (under the skin) injections
Study NCT03710603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be given at a dose of 1800 mg SC weekly in Cycles 1 and 2, then every 2 weeks in Cycles 3-6. In maintenance Cycles 7+, subjects will receive daratumumab once every 4 weeks until disease progression or unacceptable toxicity. MRD-negative subjects will stop daratumumab after sustained MRD negativity for 12 months \& after a min. of 24 months of maintenance. Daratumumab should be restarted at recurrence of MRD or confirmed loss of CR without disease progression.
Study NCT03710603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Bortezomib will be given at a dose of 1.3 mg/m2 SC twice a week (Days 1, 4, 8, and 11) in Cycles 1-6; four 28-day induction cycles (Cycles 1 to 4), and two 28-day consolidation cycles (Cycles 5-6). Subjects will not receive bortezomib after Cycle 6. On treatment days when both bortezomib and daratumumab are administered, bortezomib must be administered after the daratumumab administration.